Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; generally favorable tolerability profile

RECLAIM and IMPACT findings presented at AASLD further support the differentiated profile of pemvidutide, with its balanced 1:1 glucagon/GLP-1 dual receptor activity

Company scheduled to hold End-of-Phase 2 meeting with FDA in December on design of the Phase 3 registrational program for AUD

MORRISTOWN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist, in serious liver diseases, today presented key positive results from the RECLAIM Phase 2 trial evaluating pemvidutide in adults with moderate-to-severe alcohol use disorder (AUD). The presentation took place in a late-breaker session at The Liver Meeting® 2026, hosted by the American Association for the Study of Liver Diseases (AASLD) in Denver, Colorado.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.